TX-MARY-KAY
Mary Kay Inc., a global beauty brand renowned for its commitment to female empowerment and entrepreneurship, is thrilled to announce that its products will now be sold in Denmark. This strategic move marks a significant milestone in Mary Kay's mission to enrich women's lives across the globe. With this launch, Mary Kay products are now available in all the Scandinavian and Nordic markets in partnership with Lesley Cosmetics, Mary Kay’s authorized distributor in Scandinavia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502841084/en/
Mary Kay Inc., a global beauty brand renowned for its commitment to female empowerment and entrepreneurship, is thrilled to announce that its products will now be sold in Denmark. Denmark, known for its strong focus on gender equality and women's rights, stands as one of the most egalitarian societies in the world, ranking third in the EU on the Gender Equality Index. (Photo: Mary Kay Inc.)
Denmark, known for its strong focus on gender equality and women's rights, stands as one of the most egalitarian societies in the world, ranking third in the EU on the Gender Equality Index1. The country’s demand for innovative opportunities for women is ever-present. The availability of Mary Kay products in the Danish market promises to offer exciting, new prospects for female entrepreneurship and empowerment through its unique business model.
Mary Kay Europe President Tara Eustace expressed her excitement about the introduction of Mary Kay products into a new country. “The expansion into Denmark not only represents an amazing growth strategy in Europe but also reaffirms our commitment to providing women with unparalleled opportunities for empowerment and entrepreneurship. We are excited to partner with Lesley Cosmetics to introduce Danish women to our high-quality products and the unique Mary Kay business opportunity. Together, we look forward to building a strong community of independent beauty consultants in Denmark and supporting them in achieving their goals.”
"The essence of Mary Kay's vision has always been to offer women unparalleled opportunities for personal and professional growth,” said Carl Henric Wallblom, CEO of Lesley Cosmetics. “I am confident that Danish women will embrace Mary Kay's high-quality skincare and color cosmetics, and more importantly, the chance to achieve their entrepreneurial dreams without compromising their personal and family lives. Mary Kay's visionary business model is more relevant today than ever before, and I'm excited to see its impact on families in Denmark.”
The official grand opening in Denmark, attended by 750 guests, was a spectacular and historic evening for Mary Kay, Lesley Cosmetics, and the many women who have eagerly awaited the products and opportunity. Click here to watch the Mary Kay Beauty Beyond Borders video.
Mary Kay's legacy of enriching women's lives for over 60 years continues to inspire and pave the way for future generations. With its cutting-edge skincare and color cosmetics, Mary Kay is set to make a significant impact in Denmark, empowering women to pursue their dreams and achieve success on their own terms.
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly Twitter).
1 Source: European Institute For Gender Equality (2023). Retrieved from: https://eige.europa.eu/gender-equality-index/2023/country/DK.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502841084/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom